# The role of aetiology in determining anticoagulation effectiveness for the treatment of left ventricular thrombus

**Authors:** Johanna Jones, Holly Morgan, Krishnaraj Rathod, Robert O’Dowling, Christopher Pieri, Bianca Coldea, Benjamin Waters, Paul Wright, Sotiris Antoniou, Andrew Wragg, Amedeo Chiribiri, Anthony Mathur, Divaka Perera, Daniel A Jones

PMC · DOI: 10.1093/ehjcvp/pvaf091 · European Heart Journal. Cardiovascular Pharmacotherapy · 2025-12-31

## TL;DR

This study finds that the cause of heart issues affects how well blood thinners work for treating heart clots.

## Contribution

The study reveals that treatment outcomes for left ventricular thrombus depend on the underlying heart condition.

## Key findings

- DOACs showed better clot resolution in AMI patients compared to VKA.
- DOACs were linked to higher SSE rates in non-ischaemic cardiomyopathy.
- Aetiology strongly influences treatment response and safety outcomes.

## Abstract

Left ventricular (LV) thrombus is a severe complication of acute myocardial infarction (AMI) and chronic heart failure. While current guidelines support the use of direct oral anticoagulants (DOACs) as alternatives to vitamin K antagonists (VKA), their benefit across different aetiologies remains uncertain. This study aimed to compare the efficacy and safety of DOAC vs. VKA across different aetiologies of LV dysfunction.

We conducted a multi-centre observational study including 901 patients with confirmed LV thrombus treated with either a VKA or DOAC. The primary outcome was thrombus resolution, secondary outcomes included stroke and systemic embolization (SSE), major bleeding and mortality with analyses performed by aetiology. The principal aetiologies were AMI (38.3%), ischaemic cardiomyopathy (ICM) (38.0%) and non-ischaemic cardiomyopathy (NICM) (23.7%). Overall, thrombus resolution was significantly higher in DOAC treated patients, but this was driven by the AMI sub-group (P = 0.018). Direct oral anticoagulant use independently predicted thrombus resolution (OR 2.0, 95% Cl 1.29–3.24, P = 0.010). Major bleeding events (BARC ≥3) were more common with VKA use (P = 0.008). Non-ischaemic cardiomyopathy had the highest SSE rate (15.3%, P = 0.002), which were significantly raised in those treated with DOAC (P < 0.001).

The underlying aetiology of LV dysfunction significantly influences both treatment response and outcomes in patients with LV thrombus. Direct oral anticoagulant were associated with superior efficacy and safety in AMI-related LV thrombus, but were linked to increased rates of SSE in NICM. These findings highlight the importance of aetiology on LV thrombus management and the potential need for tailored approaches.

Graphical Abstract

## Linked entities

- **Diseases:** acute myocardial infarction (MONDO:0004781)

## Full-text entities

- **Diseases:** bleeding (MESH:D006470), stroke (MESH:D020521), LV thrombus (MESH:D013927), LV dysfunction (MESH:D018487), heart failure (MESH:D006333), ICM (MESH:D009202), AMI (MESH:D009203)
- **Chemicals:** DOAC (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12946968/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12946968/full.md

## References

27 references — full list in the complete paper: https://tomesphere.com/paper/PMC12946968/full.md

---
Source: https://tomesphere.com/paper/PMC12946968